Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging once-daily GSK233705B in COPD
2007-006287-29Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of darotropium bromide in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by GSK. Primary endpoint: Change from baseline in clinic visit trough FEV1. Started Apr 2008; status: completed.
02
Drugs
darotropium bromide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2007-006287-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006287-29.